1. Home
  2. ALLO vs GHM Comparison

ALLO vs GHM Comparison

Compare ALLO & GHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • GHM
  • Stock Information
  • Founded
  • ALLO 2017
  • GHM 1936
  • Country
  • ALLO United States
  • GHM United States
  • Employees
  • ALLO N/A
  • GHM N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • GHM Industrial Machinery/Components
  • Sector
  • ALLO Health Care
  • GHM Industrials
  • Exchange
  • ALLO Nasdaq
  • GHM Nasdaq
  • Market Cap
  • ALLO 438.2M
  • GHM 480.7M
  • IPO Year
  • ALLO 2018
  • GHM N/A
  • Fundamental
  • Price
  • ALLO $1.82
  • GHM $44.68
  • Analyst Decision
  • ALLO Strong Buy
  • GHM Buy
  • Analyst Count
  • ALLO 10
  • GHM 1
  • Target Price
  • ALLO $10.06
  • GHM $35.00
  • AVG Volume (30 Days)
  • ALLO 3.1M
  • GHM 92.0K
  • Earning Date
  • ALLO 03-13-2025
  • GHM 02-03-2025
  • Dividend Yield
  • ALLO N/A
  • GHM N/A
  • EPS Growth
  • ALLO N/A
  • GHM 172.71
  • EPS
  • ALLO N/A
  • GHM 0.71
  • Revenue
  • ALLO $43,000.00
  • GHM $196,402,000.00
  • Revenue This Year
  • ALLO N/A
  • GHM $13.21
  • Revenue Next Year
  • ALLO N/A
  • GHM $9.89
  • P/E Ratio
  • ALLO N/A
  • GHM $62.82
  • Revenue Growth
  • ALLO 26.47
  • GHM 11.88
  • 52 Week Low
  • ALLO $1.78
  • GHM $18.90
  • 52 Week High
  • ALLO $5.78
  • GHM $49.28
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 36.69
  • GHM 55.32
  • Support Level
  • ALLO $2.11
  • GHM $40.50
  • Resistance Level
  • ALLO $2.10
  • GHM $49.28
  • Average True Range (ATR)
  • ALLO 0.17
  • GHM 2.06
  • MACD
  • ALLO -0.02
  • GHM -0.14
  • Stochastic Oscillator
  • ALLO 5.69
  • GHM 47.61

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About GHM Graham Corporation

Graham Corporation designs and manufactures mission-critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries. The company also services and sells spare parts for its equipment. It designs and manufactures custom-engineered vacuum, heat transfer, cryogenic pump and turbomachinery technologies.

Share on Social Networks: